Agah Ramtin 4

What Happened Agah Ramtin, Chief Medical Officer and a director of RenovoRx, reported an open-market purchase of 10,000 shares of RenovoRx (RNXT) on January 21, 2026. The filing shows a weighted average price of about $1.00 per share for a reported total purchase value of $9,975. This was a purchase (transaction code P), which is a direct acquisition of stock rather than a sale or option exercise.

Key Details

• Transaction date: 2026-01-21 (reported on Form 4 filed 2026-01-22). Filing appears timely.
• Price: weighted average ~$1.00/share; per-share prices ranged from $0.995 to $1.00 (footnote).
• Shares acquired: 10,000 shares; reported aggregate purchase value $9,975.
• Shares owned after transaction: not specified in the filing.
• Footnotes: F1 notes open-market purchases; F2 explains the weighted average price and multiple executions.
• No 10b5-1 plan, tax withholding, gifts, or option exercises were disclosed in this filing.

Context Open-market purchases by officers are straightforward purchases of common stock and can be seen as a modest insider buy (here ~ $10k). This single small purchase is factual information—use it with other data (company trends, financials, and broader insider activity) when evaluating investment decisions.